<p>过去一周，几只生物科技股票的强势减弱，在 Benzinga 的边缘股票排名中，它们的动量评分出现了显著下降。</p>
<h2>动量评分下降的四大生物科技股票</h2>
<p>在 Benzinga 的边缘排名中，动量是基于股票的相对强度计算的，考虑了其价格波动和多个时间框架内的波动性，并与其他股票进行百分位排名。</p>
<p>在过去一周，以下生物科技股票的动量评分大幅下降，原因是什么呢？</p>
<p><strong>另见：史蒂文·科恩的生物科技投资变得更加大胆——同时也更小</strong></p>
<h3>1. Capricor Therapeutics Inc.</h3>
<p><strong>Capricor Therapeutics Inc.</strong>（纳斯达克股票代码：CAPR）的股票在 FDA 发出拒绝其针对杜氏肌营养不良症的细胞疗法 Deramiocel 申请的完整回应信后失去了动力。该机构指出了疗效问题和公司生产流程的问题。</p>
<p>该股票年初至今下跌了 57.69%，过去一个月下跌了 17.58%，其动量评分在短短一周内从 77.57 降至 22.12。</p>
<p></p>
<p>根据 <strong>Benzinga 的边缘股票排名</strong>，该股票在动量和价值方面得分较低，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票的更深入见解。</p>
<h3>2. Lava Therapeutics NV</h3>
<p>荷兰生物科技公司 <strong>Lava Therapeutics NV</strong>（纳斯达克股票代码：LVTX）的动量评分下降了 46.74 点，从 82.03 降至 35.29。</p>
<p>该股票在公司发布超出预期的第二季度净亏损后失去了动量，紧接着 Jefferies 将其评级从 “买入” 下调至 “持有”。</p>
<p></p>
<p>在 <strong>Benzinga 的边缘股票排名</strong> 中，该股票在动量和价值方面得分较低，但短期、中期和长期的价格趋势较为有利。点击 这里 获取该股票的更深入见解。</p>
<h3>3. Alaunos Therapeutics Inc.</h3>
<p>临床阶段肿瘤学公司 <strong>Alaunos Therapeutics Inc.</strong>（纳斯达克股票代码：TCRT）的动量在一周内下降了 31.48 点，从 56.44 降至 24.96，主要是由于该股票自 7 月中旬以来的急剧下跌，且没有主要催化剂或基本面新闻可归咎于此。</p>
<p>该股票年初至今仍上涨 15.74%，在 7 月第二周从 52 周高点 6.20 美元下跌了 63%。</p>
<p></p>
<p>该股票的动量评分较低，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票、其同行和竞争对手的更深入见解。</p>
<h2>4. Champions Oncology Inc.</h2>
<p>总部位于新泽西的 <strong>Champions Oncology Inc.</strong>（纳斯达克股票代码：CSBR）在其令人失望的第二季度业绩后承受压力，报告了收入下降和亏损扩大。该股票年初至今下跌了 13.90%，从今年年初的 52 周高点下跌了 41.1%，导致其动量评分下降了 26.44 点，从 78.47 降至 52.03。</p>
<p></p>
<p>该股票在动量方面得分较高，但在价值和质量方面表现不佳，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票的更深入见解。</p>
<p><strong>阅读更多：</strong></p>
<ul>
<li><strong>动量强劲的五大生物科技股票</strong></li>
</ul>
<p><em>图片来源：Shutterstock</em></p>

TCRT

CSBR

<p>几只生物科技股票在过去一周的动量评分上出现了下降，显示出实力减弱。值得注意的股票包括 Capricor Therapeutics，该公司在 FDA 拒绝其治疗申请后大幅下跌，以及 Lava Therapeutics，该公司在遭遇超出预期的亏损后评级被下调。Alaunos Therapeutics 在没有重大新闻的情况下也出现了下滑，而 Champions Oncology 则报告了令人失望的财报，导致其动量评分下降。总体来看，根据 Benzinga 的边缘股票排名，这些股票在动量和价值方面显示出不利趋势</p>

<p>Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga’s Edge Stock Rankings witnessing a significant decline.</p>
<div class="lb-trans"><p>过去一周，几只生物科技股票的强势减弱，在 Benzinga 的边缘股票排名中，它们的动量评分出现了显著下降。</p>
</div><h2>Top 4 Biotech Stocks With A Dip In Momentum Scores</h2>
<div class="lb-trans"><h2>动量评分下降的四大生物科技股票</h2>
</div><p>In Benzinga’s Edge Rankings, Momentum is calculated based on the relative strength of a stock, taking into consideration its price movements and volatility across multiple time frames, ranked as a percentile against other stocks.</p>
<div class="lb-trans"><p>在 Benzinga 的边缘排名中，动量是基于股票的相对强度计算的，考虑了其价格波动和多个时间框架内的波动性，并与其他股票进行百分位排名。</p>
</div><p>Over the past week, the following biotech stocks have seen big declines in their respective momentum scores, and here’s why?</p>
<div class="lb-trans"><p>在过去一周，以下生物科技股票的动量评分大幅下降，原因是什么呢？</p>
</div><p><strong>See Also: Steven Cohen’s Biotech Bets Are Getting Bolder — And Smaller</strong></p>
<div class="lb-trans"><p><strong>另见：史蒂文·科恩的生物科技投资变得更加大胆——同时也更小</strong></p>
</div><h3>1. Capricor Therapeutics Inc.</h3>
<div class="lb-trans"><h3>1. Capricor Therapeutics Inc.</h3>
</div><p>Shares of <strong>Capricor Therapeutics Inc.</strong>(NASDAQ: CAPR) have lost steam after the FDA issued a Complete Response Letter rejecting its application for Deramiocel, a cell therapy targeting Duchenne muscular dystrophy. The agency flagged both efficacy concerns and issues with the company's manufacturing processes.</p>
<div class="lb-trans"><p><strong>Capricor Therapeutics Inc.</strong>（纳斯达克股票代码：CAPR）的股票在 FDA 发出拒绝其针对杜氏肌营养不良症的细胞疗法 Deramiocel 申请的完整回应信后失去了动力。该机构指出了疗效问题和公司生产流程的问题。</p>
</div><p>The stock is down 57.69% year-to-date, and 17.58% over the past month, leading its Momentum scores to drop from 77.57 to 22.12 within just one week.</p>
<div class="lb-trans"><p>该股票年初至今下跌了 57.69%，过去一个月下跌了 17.58%，其动量评分在短短一周内从 77.57 降至 22.12。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>According to <strong>Benzinga’s Edge Stock Rankings</strong>, the stock scores poorly on Momentum and Value, with an unfavorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>根据 <strong>Benzinga 的边缘股票排名</strong>，该股票在动量和价值方面得分较低，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票的更深入见解。</p>
</div><h3>2. Lava Therapeutics NV</h3>
<div class="lb-trans"><h3>2. Lava Therapeutics NV</h3>
</div><p>Dutch biotech company, <strong>Lava Therapeutics NV</strong> (NASDAQ: LVTX), is down 46.74 points in its Momentum score, dropping from 82.03 to 35.29.</p>
<div class="lb-trans"><p>荷兰生物科技公司 <strong>Lava Therapeutics NV</strong>（纳斯达克股票代码：LVTX）的动量评分下降了 46.74 点，从 82.03 降至 35.29。</p>
</div><p>The stock lost its momentum after the company posted a wider-than-expected second-quarter net loss, which was quickly followed by a rating downgrade by Jefferies, from a “Buy” to a “Hold.”</p>
<div class="lb-trans"><p>该股票在公司发布超出预期的第二季度净亏损后失去了动量，紧接着 Jefferies 将其评级从 “买入” 下调至 “持有”。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock scores poorly on Momentum and Value in <strong>Benzinga’s Edge Stock Rankings</strong>, but has a favorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>在 <strong>Benzinga 的边缘股票排名</strong> 中，该股票在动量和价值方面得分较低，但短期、中期和长期的价格趋势较为有利。点击 这里 获取该股票的更深入见解。</p>
</div><h3>3. Alaunos Therapeutics Inc.</h3>
<div class="lb-trans"><h3>3. Alaunos Therapeutics Inc.</h3>
</div><p>Clinical-stage oncology company, <strong>Alanunos Therapeutics Inc.</strong> (NASDAQ: TCRT), has seen its Momentum drop 31.48 points within a week, from 56.44 to 24.96, primarily driven by the steep decline in the stock starting mid-July, with no major catalyst or fundamental news to blame.</p>
<div class="lb-trans"><p>临床阶段肿瘤学公司 <strong>Alaunos Therapeutics Inc.</strong>（纳斯达克股票代码：TCRT）的动量在一周内下降了 31.48 点，从 56.44 降至 24.96，主要是由于该股票自 7 月中旬以来的急剧下跌，且没有主要催化剂或基本面新闻可归咎于此。</p>
</div><p>The stock is still up 15.74% year-to-date, following a 63% decline from its 52-week high of $6.20 during the second week of July.</p>
<div class="lb-trans"><p>该股票年初至今仍上涨 15.74%，在 7 月第二周从 52 周高点 6.20 美元下跌了 63%。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock has a low momentum score, and has an unfavorable price trend in the short, medium and long-terms. Click here for deeper insights into the stock, its peers and competitors.</p>
<div class="lb-trans"><p>该股票的动量评分较低，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票、其同行和竞争对手的更深入见解。</p>
</div><h2>4. Champions Oncology Inc.</h2>
<div class="lb-trans"><h2>4. Champions Oncology Inc.</h2>
</div><p>New Jersey-based <strong>Champions Oncology Inc.</strong> (NASDAQ: CSBR) has been under pressure after its disappointing second quarter results, when it reported a drop in revenue, alongside widening losses. The stock is down 13.90 % year-to-date, and 41.1% from its 52-week high early this year, leading to a 26.44 point drop in its Momentum score, from 78.47 to 52.03.</p>
<div class="lb-trans"><p>总部位于新泽西的 <strong>Champions Oncology Inc.</strong>（纳斯达克股票代码：CSBR）在其令人失望的第二季度业绩后承受压力，报告了收入下降和亏损扩大。该股票年初至今下跌了 13.90%，从今年年初的 52 周高点下跌了 41.1%，导致其动量评分下降了 26.44 点，从 78.47 降至 52.03。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock still scores high on Momentum, but does poorly on Value and Quality, with an unfavorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>该股票在动量方面得分较高，但在价值和质量方面表现不佳，短期、中期和长期的价格趋势均不利。点击 这里 获取该股票的更深入见解。</p>
</div><p><strong>Read More:</strong></p>
<div class="lb-trans"><p><strong>阅读更多：</strong></p>
</div><ul>
<li><strong>Top 5 Biotech Stocks With Strong Momentum</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>动量强劲的五大生物科技股票</strong></li>
</ul>
</div><p><em>Photo courtesy: Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：Shutterstock</em></p>
</div>

4 只生物科技股票表现出疲软迹象：过去一周动量评分正在减弱